Madhu Kumar

Stock Analyst at Goldman Sachs

(3.51)
# 918
Out of 4,479 analysts
138
Total ratings
52.69%
Success rate
16.77%
Average return

38 Stocks

Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $105.09
Upside: +60.81%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5$6
Current: $6.10
Upside: -1.64%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23$26
Current: $30.51
Upside: -14.78%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19$17
Current: $16.37
Upside: +3.85%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $4.34
Upside: -7.83%
Cerevel Therapeutics Holdings
May 23, 2023
Maintains: Neutral
Price Target: $31$30
Current: $41.23
Upside: -27.24%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135$155
Current: $177.61
Upside: -12.73%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48$53
Current: $54.84
Upside: -3.36%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.20
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65$73
Current: $25.22
Upside: +189.45%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124$141
Current: $34.98
Upside: +303.09%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39$34
Current: $20.66
Upside: +64.57%
Iovance Biotherapeutics
Dec 9, 2022
Downgrades: Neutral
Price Target: $20$6
Current: $7.73
Upside: -22.38%
Arcturus Therapeutics Holdings
Nov 10, 2022
Maintains: Sell
Price Target: $8$14
Current: $21.48
Upside: -34.82%
Dynavax Technologies
Nov 4, 2022
Maintains: Buy
Price Target: $24$21
Current: $11.08
Upside: +89.53%
Edgewise Therapeutics
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $18.38
Upside: -72.80%
Editas Medicine
May 24, 2022
Maintains: Sell
Price Target: $10$8
Current: $4.54
Upside: +76.21%
Arvinas
May 24, 2022
Maintains: Buy
Price Target: $111$89
Current: $24.85
Upside: +258.15%
Passage Bio
Jan 19, 2022
Downgrades: Neutral
Price Target: $29$6
Current: $1.00
Upside: +500.24%
Applied Therapeutics
Aug 27, 2021
Downgrades: Sell
Price Target: n/a
Current: $4.35
Upside: -
Intellia Therapeutics
Jun 23, 2021
Maintains: Neutral
Price Target: n/a
Current: $22.15
Upside: -
Cellectis
Mar 16, 2021
Upgrades: Outperform
Price Target: n/a
Current: $1.89
Upside: -
Gritstone bio
Jan 20, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.57
Upside: -
uniQure
Jul 31, 2020
Upgrades: Outperform
Price Target: n/a
Current: $4.01
Upside: -
Arbutus Biopharma
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.13
Upside: -
Aprea Therapeutics
Apr 21, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.80
Upside: -
Vir Biotechnology
Mar 27, 2020
Maintains: Underperform
Price Target: n/a
Current: $8.85
Upside: -
Pieris Pharmaceuticals
Mar 13, 2020
Upgrades: Outperform
Price Target: $400
Current: $8.57
Upside: +4,567.44%
Scholar Rock Holding
Mar 12, 2020
Initiates: Outperform
Price Target: n/a
Current: $7.63
Upside: -
Leap Therapeutics
Feb 11, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.69
Upside: -
EyePoint Pharmaceuticals
Oct 16, 2018
Maintains: Buy
Price Target: n/a
Current: $8.01
Upside: -
Assembly Biosciences
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $13.35
Upside: +3,675.28%
Alnylam Pharmaceuticals
Aug 13, 2018
Maintains: Buy
Price Target: n/a
Current: $247.61
Upside: -
Regulus Therapeutics
Jul 6, 2018
Maintains: Neutral
Price Target: n/a
Current: $1.76
Upside: -
InflaRx
Feb 8, 2018
Initiates: Buy
Price Target: n/a
Current: $1.73
Upside: -
Akari Therapeutics,
Feb 8, 2018
Initiates: Neutral
Price Target: n/a
Current: $3.10
Upside: -
TG Therapeutics
Dec 1, 2017
Reinstates: Buy
Price Target: n/a
Current: $18.31
Upside: -
CRISPR Therapeutics AG
Mar 28, 2017
Initiates: Buy
Price Target: n/a
Current: $53.12
Upside: -